SCHEMBL3034801

SCHEMBL3034801

CCCCOC(=O)[C@H]1CN(c2ccc([C@H]3CC[S@+]([O-])CC3)c(F)c2)C(=O)O1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.52
GRM2 Q14416 11/20 0.37
MAOB P27338 2/20 0.34
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3041204 1.00 MAOA (0.52) MAOAGRM2MAOBNPSR1
SCHEMBL3041712 0.89 MAOA (0.39) MAOAGRM2MAOB
SCHEMBL3033185 0.89 MAOA (0.39) MAOAGRM2MAOB
SCHEMBL3044403 0.88 MAOA (0.54) MAOAGRM2MAOB
SCHEMBL3048565 0.86 MAOA (0.58) MAOAGRM2MAOB
SCHEMBL3039264 0.86 GRM2 (0.40) GRM2
SCHEMBL3035177 0.86 GRM2 (0.40) GRM2
SCHEMBL6040319 0.82 MAOA (0.62) MAOAMAOB
SCHEMBL5764982 0.82 MAOA (0.62) MAOAMAOB
SCHEMBL6040395 0.82 MAOA (0.75) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885GRM2 2255/4885MAOB 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.